Announcements Trials
Browse Landscape

Phase

Phase 3 2Phase 2 1

Status

Completed 3

Sponsor Class

NIH 3OTHER 1

Study Type

Interventional 3

Sponsor

Cancer Type

Genitourinary 3

Conditions

Prostatic Neoplasms 3Urinary Bladder Neoplasms 2Carcinoma, Non-Small-Cell Lung 2Oligodendroglioma 1Neoplasms, Plasma Cell 1Multiple Myeloma 1Gliosarcoma 1Glioma 1Glioblastoma 1Central Nervous System Neoplasms 1Carcinoma, Transitional Cell 1Carcinoma, Renal Cell 1Breast Neoplasms 1Brain Neoplasms 1Astrocytoma 1

Interventions

Docetaxel 26Prednisone 16Magnetic Resonance Spectroscopy 16Specimen Handling 15PROSTVAC 14Biopsy 12Goserelin 11bicalutamide 10Leuprolide 9sargramostim 8Estramustine 8Radiotherapy 7Lycopene 7High-Intensity Focused Ultrasound Ablation 7Flutamide 7Bevacizumab 7enzalutamide 6Thalidomide 6Mitoxantrone 62-(3-(1-carboxy-5-((6-fluoropyridine-3-carbonyl)amino)pentyl)ureido)pentanedioic acid 6ixabepilone 5olaparib 4cediranib 4Tomography, X-Ray Computed 4Radiation 4Nivolumab 4Magnetic Resonance Imaging 4Androgen Antagonists 4Amplified Fragment Length Polymorphism Analysis 4temsirolimus 3

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
NIH × Prostatic Neoplasms × Suramin × Clear all
NCT00002723 2013-02-28

Low, Intermediate, or High Dose Suramin in Treating Patients With Hormone-Refractory Prostate Cancer

National Cancer Institute (NCI)

Phase 3 Completed
390 enrolled
Genitourinary

Prostatic Neoplasms

NCT00002881 2010-11-09

Flutamide, Suramin, and Hydrocortisone in Treating Patients With Prostate Cancer

National Cancer Institute (NCI)

Phase 3 Completed
Genitourinary

Prostatic Neoplasms

NCT00001266 2008-03-04

A Phase II Trial of Leuprolide + Flutamide + Suramin in Untreated Poor Prognosis Prostate Carcinoma

National Institutes of Health Clinical Center (CC)

Phase 2 Completed
70 enrolled
Genitourinary

Prostatic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡